A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

This study is testing DR-0201, a new experimental drug, in patients with active autoimmune diseases including lupus (SLE or cutaneous lupus), primary Sjögren's syndrome, inflammatory muscle diseases (polymyositis/dermatomyositis), or early diffuse systemic sclerosis (a connective tissue disease affecting the skin and organs). **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with one of the following: lupus (SLE or CLE), primary Sjögren's syndrome, polymyositis/dermatomyositis, or diffuse systemic sclerosis diagnosed within the past 3 years - Your disease is active but stable, and your doctor does not expect your treatment to need changing for the next 3–4 months - You are willing to undergo tissue biopsies (skin, salivary gland, or muscle depending on your condition) - You are using effective contraception if of childbearing potential **You may NOT be eligible if...** - Your disease is not one of the specific diagnoses listed - You have lupus or cutaneous lupus with skin scores below the required threshold - You are not willing to undergo biopsies - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.